Clinical Trial Update: Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). [Phase 4]

View source ↗

Summary

Phase 4 real-world study assessing gene profiles in patients with advanced non-small cell lung cancer who progressed on first-line osimertinib; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced NSCLC | Phase 4 | Status: COMPLETED | Results posted: 2025-09-11